Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the ...
来自MSN6 天
RIGL Stock Surges 41.4% in a Year: Time to Buy or Sell?
Shares of biotechnology company Rigel Pharmaceuticals, Inc. RIGL have surged 41.4% in the past year against the industry’s ...
Nasdaq5 天
Should You Add RIGL Stock to Your Portfolio Pre-Q4 Earnings?
The company is also making good progress with its second FDA-approved product, Rezlidhia (olutasidenib). The drug is indicated for the treatment of adult patients with relapsed or refractory (R/R ...
ETF Daily News4 天
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives $36.20 Consensus Target Price from Analysts
The company’s commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non ...
Rigel制药公司CFO出售价值80,614美元股票
生物科技公司Rigel Pharmaceuticals Inc. (NASDAQ: RIGL )目前市值4.27亿美元，股价为24.39美元。公司最近报告称，执行副总裁兼首席财务官Dean Schorno出售了价值80,614美元的公司普通股。根据 InvestingPro 数据显示，该股票在过去六个月内实现了147%的显著涨幅。这些交易发生在2月4日和2月5日，分别以20.921美元的价格出售2 ...